Partnering

Partnering

Partnerships are an important part of the company’s growth strategy. The company is actively exploring alliances that complement our expertise in new uses for previously approved drugs and new molecular entity development with important scientific, clinical and business capabilities. These alliances may incorporate our intellectual property, product candidates and product development capabilities.

To inquire regarding partnership opportunities with Ampio Pharmaceuticals, please contact:

Ampio Pharmaceuticals, Inc.
5445 DTC Parkway, Suite 925
Greenwood Village, CO 80111 USA
Tel: +1 720-437-6500
Fax: +1 720-437-6501

E-mail Business Development

Learn More About:

Premature Ejaculation (PE)

Premature ejaculation is a distressing male sexual dysfunction that is more common than erectile dysfunction (ED) and has a major impact on the quality of life for men and their sexual partners.

Diabetic Retinopathy

A complication of diabetes mellitus that damages the retina in the eyes and leads to blindness

Diabetic Nephropathy

A progressive complication of diabetes mellitus that leads to end-stage renal disease (ESRD) requiring kidney transplantation or chronic dialysis

AMPE Stock Quote - delayed
Last Change
AMPE 2.67 Down 0.14 (4.98%)

Ampio News

05/14/2012 | Press Release

Ampio Pharmaceuticals Schedules 2012 Update Webcast

05/11/2012 | Press Release

Ampio Pharmaceuticals Reports Pre-IND Meeting With the FDA to Obtain Clinical Path Guidance for Ampion™ for the Treatment of Chronic Pain of Osteoarthritis of the Knee and Schedules May 16th Webcast to Update Shareholders

04/30/2012 | Press Release

Ampio Pharmaceuticals announces extended analysis of Ampion™ In the Knee (AIK) Study shows pain relief of osteoarthritis, 84 days after a single injection into the knee, is statistically significant

» See all Ampio news